[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hf---heart-failure\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hf---heart-failure":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,44,79,101,128],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100643552","ai-ecg-algorithm-for-detecting-lv-systolic-dysfunction-100643552",false,"NCT07636759","AI ECG Algorithm for Detecting LV Systolic Dysfunction","Prospective Observational Cohort Study of Deep Learning-based ECG Algorithm for Detecting Left Ventricular Systolic Dysfunction","Inclusion Criteria:\n\n* Adults aged ≥19 years.\n* Patients who underwent both transthoracic echocardiography and 12-lead electrocardiography (ECG) at Ajou University Hospital in the outpatient, inpatient, or emergency department setting.\n* ECG and echocardiography performed within 30 days of each other.\n\nExclusion Criteria:\n\n* Interval between ECG and echocardiography greater than 30 days.\n* Missing or corrupted original ECG waveform data (XML or HL7 format).\n* Presence of an implanted cardiac device, including a permanent pacemaker, implantable cardioverter-defibrillator (ICD), or cardiac resynchronization therapy (CRT) device.\n* Missing age, sex, or left ventricular ejection fraction (LVEF) data.","ALL","19 Years",{"count":19,"type":20},1500,"ESTIMATED","1 Month","OBSERVATIONAL","This prospective observational cohort study aims to evaluate the clinical performance of a deep learning-based electrocardiography (ECG) algorithm (DeepECG LVSD) for detecting left ventricular systolic dysfunction (LVSD), defined as left ventricular ejection fraction (LVEF) ≤40%, using transthoracic echocardiography as the reference standard. Approximately 15,000 adult patients undergoing both ECG and echocardiography within 30 days at Ajou University Hospital will be enrolled. Diagnostic performance will be assessed using the area under the receiver operating characteristic curve (AUROC), sensitivity, specificity, positive predictive value, negative predictive value, and accuracy. Secondary analyses will evaluate the association between AI-predicted LVSD and 30-day clinical outcomes, including all-cause mortality, emergency department visits, and heart failure rehospitalization.",[25],"HF - Heart Failure",[27,28,29,30],"Heart failure","ECG","Artificial Intelligence","Deep Learning","RECRUITING","2026-08-05",{"date":34,"type":35},"2026-08-07","ACTUAL",{"date":37,"type":35},"2026-01-01",{"date":39,"type":20},"2027-12-31",{"name":41,"class":42},"Ajou University School of Medicine","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":64,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":43},"100648998","exercise-based-cardiac-rehabilitation-for-patients-with-heart-failure-with-preserved-ejection-fraction-empower-hfpef-100648998","NCT07727096","Exercise-Based Cardiac Rehabilitation for Patients With Heart Failure With Preserved Ejection Fraction (EMPOWER-HFpEF)","Effects of a Supervised Exercise Training Program on Clinical Outcomes, Functional Capacity, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction (EMPOWER-HFpEF)","EMPOWER-HFpEF","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Diagnosis of heart failure with preserved ejection fraction (HFpEF) according to current clinical guidelines, defined by: a) signs and\u002For symptoms of heart failure; b) left ventricular ejection fraction ≥50%; c) elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP) (≥220 pg\u002FmL); and, d) objective evidence of structural and\u002For functional cardiac abnormalities consistent with HFpEF.\n* High-risk clinical profile, defined by at least one of the following: a) hospitalization for acute or worsening heart failure within the previous 120 days; b) outpatient worsening heart failure within the previous 120 days requiring emergency department evaluation or intensification of oral or intravenous diuretic therapy in a specialized heart failure clinic; c) recent diagnosis of symptomatic HFpEF (≤120 days) with New York Heart Association (NYHA) functional class II-III; or d) stable symptomatic HFpEF (NYHA class II-III) with at least two of the following comorbidities: hypertension, diabetes mellitus, obesity (body mass index ≥30 kg\u002Fm²), chronic kidney disease, dyslipidemia, obstructive sleep apnea, or stable coronary artery disease, together with elevated NT-proBNP (≥220 pg\u002FmL in patients in sinus rhythm or ≥600 pg\u002FmL in patients with atrial fibrillation).\n* Clinically stable at the time of enrollment, with no requirement for intravenous therapy or major changes in heart failure treatment during the previous 2 weeks.\n* Considered by the investigator to be able to participate in a structured exercise-based cardiac rehabilitation program safely.\n* Able and willing to provide written informed consent before any study-specific procedures.\n\nExclusion Criteria:\n\n* Inability to safely participate in a structured exercise-based cardiac rehabilitation program because of severe neurological or musculoskeletal disorders, significant cognitive impairment, or severe psychiatric illness that, in the opinion of the investigator, would interfere with study participation.\n* Clinically unstable heart failure at the time of enrollment, defined by the need for intravenous therapy, recent major changes in heart failure treatment, or ongoing heart failure decompensation.\n* Severe valvular heart disease considered to be the primary cause of the patient's symptoms.\n* Acute coronary syndrome, unstable angina, or coronary revascularization within the previous 2 weeks.\n* Uncontrolled hypertension, defined as resting systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg, or resting heart rate ≥110 beats\u002Fmin despite guideline-directed medical therapy.\n* Severe primary pulmonary disease predominantly limiting functional capacity, including significant pulmonary hypertension, chronic thromboembolic pulmonary disease, or severe chronic obstructive pulmonary disease.\n* Primary cardiomyopathy or known infiltrative heart disease.\n* Severe non-cardiac comorbidity associated with an estimated life expectancy of less than 1 year, in the opinion of the investigator.\n* Inability to provide written informed consent or to comply with study procedures and follow-up requirements.","18 Years",{"count":54,"type":20},390,"INTERVENTIONAL",[57],"NA","Heart failure with preserved ejection fraction (HFpEF) is a common condition among older adults. It is associated with frequent hospitalizations, impaired functional capacity, reduced quality of life, and high healthcare utilization. Despite recent advances in pharmacological therapy, many patients continue to experience recurrent clinical deterioration and functional decline. Exercise-based cardiac rehabilitation has demonstrated benefits in improving physical performance and quality of life. Still, its effect on long-term clinical outcomes in patients with high-risk HFpEF has not been established.\n\nThe EMPOWER-HFpEF study is a multicenter, randomized, controlled trial designed to evaluate whether an early, individualized, multimodal exercise-based cardiac rehabilitation program improves clinical outcomes compared with usual care in patients with HFpEF. Eligible participants will be randomly assigned in a 1:1 ratio to receive either usual care alone or usual care plus a structured 12-month exercise-based cardiac rehabilitation program. The intervention includes an initial 6-month supervised phase, followed by a 6-month hybrid phase combining supervised sessions with structured home- or community-based exercise to promote long-term adherence and maintenance of physical activity.\n\nThe primary objective is to determine whether this rehabilitation strategy reduces adverse clinical outcomes, including all-cause mortality, heart failure hospitalizations, all-cause hospitalizations, and outpatient heart failure decompensation, while improving functional capacity and health-related quality of life over 12 months. The results of this study will provide evidence on the effectiveness of a long-term multimodal exercise-based cardiac rehabilitation program as part of the comprehensive management of patients with HFpEF.",[25,60,61,62,63],"HFpEF - Heart Failure With Preserved Ejection Fraction","Readmission Rates","Exercise Training","Cardiac Rehab",[65,66,67,68],"Heart Failure with Preserved Ejection Fraction","Cardiac Rehabilitation","Quality of Life","Readmission","NOT_YET_RECRUITING","2026-07-22",{"date":72,"type":35},"2026-07-27",{"date":74,"type":20},"2026-09-01",{"date":76,"type":20},"2031-09-01",{"name":78,"class":42},"Fundación para la Investigación del Hospital Clínico de Valencia",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":55,"phases":88,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":43},"100630370","a-clinical-study-on-the-effect-of-cardiopulmonary-function-and-quality-of-life-in-patients-with-acute-coronary-syndrome-complicated-by-heart-failure-by-lying-sitting-standing-sequential-baduanjin-100630370","NCT07486791","A Clinical Study on the Effect of Cardiopulmonary Function and Quality of Life in Patients With Acute Coronary Syndrome Complicated by Heart Failure by \"Lying-Sitting-Standing\" Sequential Baduanjin","Inclusion Criteria:\n\n* Patients meeting the diagnostic criteria for ACS (including unstable angina, non-ST-segment elevation myocardial infarction, and ST-segment elevation myocardial infarction)\n* Complicated by heart failure during hospitalization\n* Age ≤ 85 years\n* Muscle strength ≥ grade 3\n* No history of mental illness, conscious and able to cooperate independently with this study\n* Voluntarily participate in this study and sign the informed consent form\n\nExclusion Criteria:\n\n* Patients with persistent heart failure symptoms or NYHA functional class IV despite optimal pharmacological therapy;\n* Patients with contraindications to cardiac rehabilitation, such as uncontrolled hypertension, uncontrolled arrhythmias, or hemodynamic instability;\n* Patients with untreated structural heart disease, such as heart failure caused by valvular heart disease or congenital heart disease;\n* Patients in the acute phase of various diseases, such as severe infection, deep vein thrombosis, or severe hepatic or renal failure;\n* Patients with disabilities, bone or joint diseases, or neurological disorders that preclude participation in Baduanjin exercises;\n* Patients with a life expectancy of less than one year;\n* Patients currently participating in other clinical trials.","85 Years",{"count":87,"type":20},65,[57],"This study investigates the effects of a sequential \"lying-sitting-standing\" Baduanjin intervention on patients with acute coronary syndrome complicated by heart failure. By evaluating cardiopulmonary function and quality of life through indicators such as echocardiography, NT-proBNP, 6MWT, NYHA classification, and SF-36, we aim to compare its efficacy with conventional treatment. The objective is to provide new insights for early cardiac rehabilitation strategies in patients with acute coronary syndrome complicated by heart failure",[91,25],"ACS (Acute Coronary Syndrome)","2026-04-29",{"date":94,"type":35},"2026-05-05",{"date":96,"type":35},"2026-03-10",{"date":98,"type":20},"2027-06-01",{"name":100,"class":42},"Xiling Qi",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":109,"sex":16,"minAge":52,"maxAge":110,"enrollmentInfo":111,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":113,"conditions":114,"keywords":118,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":124,"leadSponsor":125,"locationsCount":127},"100617472","left-ventricular-myocardial-work-for-predicting-response-to-crt-100617472","NCT07319065","Left Ventricular Myocardial Work for Predicting Response to CRT","Left Ventricular Myocardial Work for Predicting Response to Cardiac Resynchronization Therapy (CRT): A Multi-Center Study","CARE-MW","Healthy Adults Group\n\nInclusion Criteria:\n\n* Participants must meet all of the following criteria to be enrolled:\n\n  1. Of Han Chinese ethnicity\n  2. Aged 18-79 years\n  3. Normal blood pressure (\\\u003C 140\u002F90 mmHg)\n  4. Normal fasting blood glucose\n  5. Normal blood lipid levels (triglycerides, total cholesterol, low-density lipoprotein, high-density lipoprotein)\n  6. Normal complete blood count results (hemoglobin concentration, white blood cell count, red blood cell count, platelet count)\n  7. Normal liver and renal function (alanine transaminase \\\u003C 2× upper limit of normal; normal creatinine and blood urea nitrogen)\n  8. Normal electrocardiogram results (occasional atrial premature beats may be enrolled at the investigator's discretion)\n  9. No structural heart disease and normal cardiac function confirmed by echocardiography\n\nExclusion Criteria:\n\nParticipants will be excluded if they meet any of the following criteria:\n\n1. Clinically significant cardiac valve regurgitation (≥ mild severity)\n2. Respiratory diseases: acute or chronic respiratory disorders\n3. Endocrine diseases: thyroid disease, diabetes mellitus, hyperaldosteronism, pheochromocytoma, etc.\n4. Abnormal liver function (alanine transaminase \\> 2× upper limit of normal), abnormal renal function (elevated creatinine beyond normal range), or dyslipidemia (elevated triglycerides, total cholesterol, low-density lipoprotein, or high-density lipoprotein)\n5. Other systemic diseases: anemia, malignancy, connective tissue disease, large artery\u002Fperipheral vascular diseases (aortic dilation, aortic dissection, coarctation of the aorta, Takayasu arteritis, atherosclerosis), etc.\n6. Pregnant or lactating women\n7. Professional athletes\n8. Poor-quality ultrasound images that cannot support parameter measurement and analysis\n\nHeart failure patients with LBBB who are scheduled for CRT treatment Group\n\nInclusion criteria:\n\n1. LVEF ≤ 35%\n2. QRS ≥ 150ms; LBBB\n3. At least 3 months of optimal drug therapy before implantation\n\nExclusion Criteria:\n\n1. Suffering from connective tissue diseases such as systemic lupus erythematosus, polymyositis, and rheumatoid arthritis;\n2. Having a history of blood diseases and severe systemic diseases such as infections;\n3. Those who cannot cooperate with the examinations.\n\nPatients with LBBB who have preserved LVEF Group\n\nInclusion criteria:\n\n1. LVEF≥53%\n2. LBBB\n\nExclusion Criteria:\n\n1. Suffering from connective tissue diseases such as systemic lupus erythematosus, polymyositis, and rheumatoid arthritis;\n2. Having a history of blood diseases and severe systemic diseases such as infections;\n3. Those who cannot cooperate with the examinations.\n\nPatients with reduced LVEF but without LBBB Group\n\nInclusion criteria:\n\n1. LVEF ≤ 35%\n2. non-LBBB\n\nExclusion Criteria:\n\n1. Suffering from connective tissue diseases such as systemic lupus erythematosus, polymyositis, and rheumatoid arthritis;\n2. Having a history of blood diseases and severe systemic diseases such as infections;\n3. Those who cannot cooperate with the examinations.",true,"79 Years",{"count":112,"type":20},3240,"This study aims to establish the normal reference values for left ventricular myocardial work in healthy Chinese adults and the influencing factors. Non-invasive myocardial work serves as a new parameter for identifying CRT responders and provides a scoring system for predicting the efficacy of CRT in clinical practice. CRT can improve cardiac function and quality of life, and reduce mortality and hospitalization rates due to heart failure (HF). Currently, the number of CRT treatments is increasing year by year, but even when strictly following the indications, approximately 30% of patients do not respond. Therefore, precise prediction of CRT efficacy is of great clinical significance for improving prognosis. Currently, the indications for CRT mainly rely on clinical, electrocardiogram (CLBBB), and LVEF. By correcting ventricular contraction asynchrony to improve systolic function, however, CLBBB indicates electrical asynchrony, and LVEF improvement depends on mechanical synchrony. If the mechanical asynchrony of the ventricles can be evaluated directly before surgery, it will help predict the efficacy of CRT. Myocardial work is a recently developed non-invasive method that combines LV afterload with the overall longitudinal strain (GLS) analysis of echocardiography. Myocardial work reflects the contraction ability of the heart, stroke work, residual myocardial contraction ability, myocardial oxygen consumption, useless work, useful work, etc., and is represented by the pressure-volume loop analysis, thus having the potential to predict the efficacy of CRT. Therefore, this study intends to adopt the left ventricular myocardial work technique, combined with the current indication criteria, to predict the long-term efficacy of patients with heart failure who are scheduled for CRT treatment, thereby increasing the response rate of CRT and improving the prognosis of patients. Currently, there are no normal reference values for left ventricular myocardial work in healthy Chinese adults. Therefore, our center has initiated this multicenter clinical research project, collaborating with multiple ultrasound centers across the country, aiming to establish the normal ultrasound values for left ventricular myocardial work in healthy Chinese adults, providing new quantitative reference basis for the diagnosis of myocardial function, assessment of the severity of myocardial lesions, and efficacy observation.",[115,116,25,117],"CRT Non-Response","LBBB","Healthy Adult",[119],"Myocardial work","2025-12-21",{"date":122,"type":35},"2026-01-06",{"date":37,"type":20},{"date":39,"type":20},{"name":126,"class":42},"First Hospital of China Medical University",82,{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":55,"phases":137,"briefSummary":138,"conditions":139,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":4},"100594850","effect-of-nurse-assessed-remote-ischemic-preconditioning-on-improving-exercise-capacity-endothelial-function-and-arterial-stiffness-in-patients-with-heart-failure-with-preserved-ejection-fraction-100594850","NCT07024810","Effect of Nurse-assessed Remote Ischemic Preconditioning on Improving Exercise Capacity, Endothelial Function, and Arterial Stiffness in Patients With Heart Failure With Preserved Ejection Fraction","PIRIC-FEp Stud","Inclusion Criteria:\n\n1. HF-PEF (diagnosis according to the ESC 2021 criteria)\n\n   1. Signs and symptoms of HF\n   2. A left ventricular ejection fraction ≥50%.\n   3. Objective evidence of cardiac structural and\u002For functional abnormalities consistent with the presence of left ventricular diastolic dysfunction\u002Felevated left ventricular filling pressures, including elevated natriuretic peptides\n2. Sedentary men and women (structured exercise \\\u003C2 x 30 min\u002Fweek).\n3. Age ≥40 years\n4. Written informed consent\n5. Clinically stable for 6 weeks\n6. Optimal medical treatment for ≥6 weeks.\n\nExclusion Criteria:\n\n1. Non-cardiac causes of HF symptoms:\n\n   * Significant valvular or coronary artery disease\n   * Uncontrolled hypertension or arrhythmias\n   * Primary cardiomyopathies\n2. Significant pulmonary disease (FEV1\\\u003C50% predicted, GOLD III-IV)\n3. Inability to exercise or conditions that may interfere with exercise intervention.\n4. Myocardial infarction within the last 3 months.\n5. Patients with diabetes and\u002For peripheral vascular disease.\n6. Signs of ischemia during maximal cardiopulmonary stress test.\n7. Comorbidity that may influence prognosis at one year.\n8. Participation in another clinical trial",{"count":136,"type":20},48,[57],"The PIRIC-FEp study will be a randomized clinical trial in sedentary patients with heart failure and stable preserved ejection fraction.\n\nObjectives: 1) To evaluate the efficacy of remote ischemic preconditioning performed by nurses, a noninvasive cardioprotective intervention that uses cycles of ischemia and reperfusion in the extremities, in improving exercise capacity, cardiac function, endothelial function and arterial stiffness, and 2) To analyze its impact on quality of life and its cost-effectiveness compared to conventional treatment.\n\nMethodology: Patients will be recruited in Health Centers in the city. Those assigned to the intervention group will wear a self-administered blood pressure cuff, inflated to 220 mmHg for 5 minutes, followed by 5 minutes of deflation, in repeated cycles four times, five days a week for three months. The control group will receive standard counseling. All participants will be examined, at baseline and at three months. Adherence will be defined as completing at least 70% of the sessions. Different parameters will be evaluated, including sociodemographic variables, patient's medical history, echocardiography, cardiopulmonary exercise test, endothelial function, arterial stiffness, quality of life, spirometry, blood tests, among others. The study will be approved by an Ethics Committee, participants will be informed and will have to sign a written consent. The statistical analysis will include three phases: verification of randomization, use of covariance models for dependent variables, and sensitivity analysis with propensity score matching. All analyses will be performed on an intention-to-treat basis.",[25],"2025-06-09",{"date":142,"type":35},"2025-06-17",{"date":144,"type":20},"2025-10-01",{"date":146,"type":20},"2027-02-28",{"name":148,"class":42},"University of Castilla-La Mancha"]